ICD-10 Coding for Myeloproliferative Neoplasms(D45.0, D45.0N, D45.0P)
Explore ICD-10 coding for Myeloproliferative Neoplasms, including Polycythemia Vera and Essential Thrombocythemia, with detailed documentation requirements.
Complete code families applicable to Myeloproliferative Neoplasms
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| D45.0 | Polycythemia Vera | Use when Polycythemia Vera is confirmed with JAK2 mutation and elevated hemoglobin/hematocrit. |
|
| D47.3 | Essential Thrombocythemia | Use when Essential Thrombocythemia is confirmed with CALR/MPL mutation and elevated platelet count. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutMyeloproliferative Neoplasms
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Myeloproliferative Neoplasms.
Failing to document mutation status
Impact
Clinical: May lead to misdiagnosis., Regulatory: Non-compliance with coding standards., Financial: Potential claim denials.
Mitigation
Ensure all genetic test results are documented.
Using unspecified codes when specific mutations are confirmed
Impact
Reimbursement: May lead to denied claims or reduced reimbursement., Compliance: Non-compliance with coding guidelines., Data Quality: Decreases accuracy of clinical data.
Mitigation
Always use specific codes like D45.0 or D47.3 when mutations are confirmed.
Genetic Testing Documentation
Impact
Lack of documentation for genetic testing results.
Mitigation
Ensure all test results are included in the patient's record.